Last update 04 Jun 2025

Fluocinolone Acetonide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6alpha,9alpha-difluoro-16alpha-hydroxyprednisolone 16,17-acetonide, 6alpha-fluorotriamcinolone acetonide, 6α,9α-difluoro-16α-hydroxyprednisolone 16,17-acetonide
+ [18]
Target
Action
agonists
Mechanism
GR agonists(Glucocorticoid receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (29 Jul 1961),
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC24H30F2O6
InChIKeyFEBLZLNTKCEFIT-VSXGLTOVSA-N
CAS Registry67-73-2

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetic macular oedema
United States
26 Sep 2014
Uveitis
United States
08 Apr 2005
Dermatitis, Atopic
United States
03 Feb 1988
Inflammation
United States
15 Feb 1963
Dermatitis
Japan
29 Jul 1961
Drug Eruptions
Japan
29 Jul 1961
Eczema
United States
29 Jul 1961
Eczema
Japan
29 Jul 1961
Insect Bites and Stings
Japan
29 Jul 1961
Keratoderma, Palmoplantar
Japan
29 Jul 1961
Measles
Japan
29 Jul 1961
Melanosis
Japan
29 Jul 1961
Prurigo
Japan
29 Jul 1961
Pruritus
Japan
29 Jul 1961
Psoriasis
Japan
29 Jul 1961
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-infectious posterior uveitisPhase 3
United States
01 Dec 2000
Macular EdemaPhase 2
United States
01 May 2009
Retinal Vein OcclusionPhase 2
United States
01 May 2009
Geographic AtrophyPhase 2
United States
01 Dec 2008
Glycogen Storage Disease Type IIPhase 2
United States
01 Dec 2008
Age Related Macular DegenerationPhase 2
United States
01 Nov 2001
Age Related Macular DegenerationPhase 2
United States
01 Nov 2001
Vision, LowPhase 1
United States
19 Mar 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
53
velbdhtruj(castfjnaol) = rumoisudsn yazbvthgvk (yebrjyaxwv )
Positive
01 May 2025
TRI-LUMA
velbdhtruj(castfjnaol) = nfcofntknc yazbvthgvk (yebrjyaxwv )
Not Applicable
39
bhzunaxgul(svyzecytqs) = xxlxnmvffp jwcwbsttbc (ifccowccqf )
Positive
19 Sep 2024
Not Applicable
200
Fluocinolone Acetonidecetonide Intravitreal Implant
dibdxhkmqv(ztattvuuty) = Median IOP (14 mmHg) remained stable from baseline to 36 months. simklvyvkv (phthpzcbpy )
Positive
19 Sep 2024
Not Applicable
8
ofiakycgck(zqwvvzynii) = Adverse events were tolerable with IOP stable at 14 [9, 19] mmHg (p= 0,123 vs baseline) mivdcbfact (etjebhfkcs )
Positive
19 Sep 2024
Not Applicable
-
Intravitreal Fluocinolone Acetonide Implantation
yfvequxvvh(qbbpovqmfd) = BCVA significantly increased after fluocinolone acetonide implantation, with improvement observed after 36 months of follow-up lwzejhcqze (ncfnddazjd )
-
19 Sep 2024
Not Applicable
-
ILUVIEN® (0.19 mg fluocinolone acetonide, FAc)
qrgdouywuy(dlirsdplwa) = five eyes (27.8%) received additional intravitreal treatments during follow-up (with a mean number of 0.8 ± 2.4 anti-VEGF and 0.4 ± 0.9 short-acting corticosteroids) to control macular edema hvqigjwmwy (gedwedvdrh )
-
19 Sep 2024
Not Applicable
-
-
pmwkoyampd(bxrbkyqoms) = wnbaqvfbsv koeatyfiln (kdotfvnyuw, 78.1)
-
19 Sep 2024
Not Applicable
-
xnwcoersoj(ruohovxydf) = n=1 vdngzkkykh (yknnqowlat )
-
19 Sep 2024
Not Applicable
-
bjonfzzjij(rtebpgnske) = bkhixwavqi mtswothjqe (zqsblybrrw )
-
19 Sep 2024
bjonfzzjij(rtebpgnske) = zzvsvotlrd mtswothjqe (zqsblybrrw )
Not Applicable
-
Fluocinolone acetonide implant (0.19mg FAc, ILUVIEN®)
apxdgdyebh(gfiztfsbqg) = Increasing of IOP due to FAc implant occurred in 32% of eyes, at some point of the follow-up, and it was treated with topical medication obtbvwwkwh (cymlfohkml )
-
19 Sep 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free